1572PA prospective phase II trial of carboplatin (CBDCA) and nab-paclitaxel (nabPTX) for advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD)Background Because of the high risk of exacerbation of ILD, patients with concomitant advanced NSCLC and ILD have been ...
Methods Chemo-nave stage IIIB/IV or postoperative recurrent SCC pts were randomly assigned to receive either cisplatin (80 mg/m2) on day 1 plus gemcitabine (1000 mg/m2) on days 1, 8 every 3 weeks or CBDCA (AUC 6 mg/ml/min) on day 1 plus nab-PTX (75 mg/m2) on days 1, 8, ...
P1.01-08 Randomized Phase II Trial of CBDCA+nab-PTX vs CDDP+GEM in Patients with Chemo-Nave Squamous Cell Lung Cancer: NJLCG1302doi:10.1016/j.jtho.2019.08.723T. HaradaY. KawashimaY. FujitaT. NakagawaK. WatanabeN. MorikawaK. Takamura...